Gangyi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gangyi Yang has a total of 467 co-authors. Here are the top co-authors by number of shared publications:
Hua Liu
Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
52 shared publicationsMengliu Yang
Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
47 shared publicationsLing Li
Key Laboratory of Diagnostic Medicine (Ministry of Education) and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, China
45 shared publications- Ling Li
Department of Clinical Biochemistry and the Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education, Chongqing Medical University, Chongqing, China
31 shared publications Guenther Boden
The Division of Endocrinology/Diabetes/Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, PA, USA
24 shared publicationsDongfang Liu
Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
21 shared publications
Latest Publications
- 19 August 2026
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 270 (3)
Empagliflozin improves gut microbial disturbances and intestinal barrier integrity in STZ-induced type 2 diabetic mice
Intestinal barrier dysfunction and gut microbiota dysbiosis contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). However, the effects of empagliflozin on the gut microbiota–intestinal barrier axis remain incompletely understood. This study investigated whether empagliflozin improves intestinal barrier integrity and gut microbiota profiles in a streptozotocin (STZ)-induced murine model of T2DM. Male C57BL/6 mice were fed a high-fat diet followed by STZ injection to induce T2DM and then treated with empagliflozin (10 mg/kg/day) for 8 weeks. Intestinal barrier-related proteins were assessed by immunofluorescence and western blotting. Gut microbial profiles were analyzed using 16S rRNA gene sequencing. Short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and inflammatory cytokines were quantified by GC–MS and ELISA. Empagliflozin treatment significantly reduced fasting blood glucose levels and attenuated weight gain in diabetic mice. Diabetic animals exhibited compromised intestinal barrier structure, accompanied by decreased tight junction protein expression (Claudin-1 and ZO-1) and enhanced TLR4/MyD88/NF-κB signaling, which were substantially alleviated following empagliflozin treatment. Concurrently, elevated inflammatory cytokines (IL-1β, IL-6, and TNF-α) and LPS levels were significantly reduced following empagliflozin treatment. Microbiome analyses revealed treatment-associated reorganization of gut microbial communities, including altered β-diversity patterns, shifts in diabetes-related taxa, and modified microbial interaction networks. In addition, empagliflozin increased fecal concentrations of key SCFAs, particularly butyrate and isohexanoate. Empagliflozin was associated with improved metabolic parameters, enhanced intestinal barrier integrity, reduced inflammation, and alterations in gut microbiota composition and predicted metabolic activity. Modulation of gut homeostasis may contribute to the therapeutic benefits of empagliflozin in T2DM.
- 19 August 2026
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 270 (3)
Empagliflozin improves gut microbial disturbances and intestinal barrier integrity in STZ-induced type 2 diabetic mice
Intestinal barrier dysfunction and gut microbiota dysbiosis contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). However, the effects of empagliflozin on the gut microbiota–intestinal barrier axis remain incompletely understood. This study investigated whether empagliflozin improves intestinal barrier integrity and gut microbiota profiles in a streptozotocin (STZ)-induced murine model of T2DM. Male C57BL/6 mice were fed a high-fat diet followed by STZ injection to induce T2DM and then treated with empagliflozin (10 mg/kg/day) for 8 weeks. Intestinal barrier-related proteins were assessed by immunofluorescence and western blotting. Gut microbial profiles were analyzed using 16S rRNA gene sequencing. Short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and inflammatory cytokines were quantified by GC–MS and ELISA. Empagliflozin treatment significantly reduced fasting blood glucose levels and attenuated weight gain in diabetic mice. Diabetic animals exhibited compromised intestinal barrier structure, accompanied by decreased tight junction protein expression (Claudin-1 and ZO-1) and enhanced TLR4/MyD88/NF-κB signaling, which were substantially alleviated following empagliflozin treatment. Concurrently, elevated inflammatory cytokines (IL-1β, IL-6, and TNF-α) and LPS levels were significantly reduced following empagliflozin treatment. Microbiome analyses revealed treatment-associated reorganization of gut microbial communities, including altered β-diversity patterns, shifts in diabetes-related taxa, and modified microbial interaction networks. In addition, empagliflozin increased fecal concentrations of key SCFAs, particularly butyrate and isohexanoate. Empagliflozin was associated with improved metabolic parameters, enhanced intestinal barrier integrity, reduced inflammation, and alterations in gut microbiota composition and predicted metabolic activity. Modulation of gut homeostasis may contribute to the therapeutic benefits of empagliflozin in T2DM.
- Open Access
- 12 February 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Acute-to-chronic glycemic ratio: a promising biomarker for prognosis of diabetic foot ulcers in a multi-center cohort study
The relationship between the acute-to-chronic glycemic ratio (ACG ratio) and diabetic foot ulcers (DFU) has not been established. This study sought to exam
- 12 February 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Open AccessAcute-to-chronic glycemic ratio: a promising biomarker for prognosis of diabetic foot ulcers in a multi-center cohort study
The relationship between the acute-to-chronic glycemic ratio (ACG ratio) and diabetic foot ulcers (DFU) has not been established. This study sought to exam
- Open Access
- 25 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1213
Cartilage Intermediate Layer Protein 2 Aggravates Hepatic Lipid Accumulation and Inflammation Through the IRE1α/XBP1 Pathway
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and is characterized by excessive lipid accumulation in hepatocytes. Endoplasmic reticulum (ER) stress and inflammation play important roles in hepatic lipid accumulation. Although CILP2 has been implicated in lipid metabolism, its role in MASLD remains unclear. Hepatic steatosis was induced in mice by a high-fat diet in this study. CILP2 was overexpressed in mouse livers and in vitro hepatocytes using the Ad-CILP2 adenovirus. CILP2 KO mice were also used in the experiments. Liver tissues and hepatocytes were collected for further analysis. CILP2 expression was upregulated in steatotic liver tissue and hepatocytes. CILP2 overexpression upregulated genes related to fatty acid synthesis (Srebp-1c, Fasn, Acc, Scd1, and Cd36), promoted lipid accumulation, and elevated the expression of proinflammatory cytokines (Il6, Tnf, and Il1b). Conversely, CILP2 knockout reduced high-fat diet-induced hepatic steatosis and improved glucose metabolism. Mechanistically, CILP2 activated the IRE1α/XBP1 branch of the ER stress pathway, thereby promoting lipid synthesis and inflammation, effects that were partially alleviated by 4-PBA and STF-083010 treatments. Our findings indicate that CILP2 contributes to hepatic lipid accumulation and inflammation via the IRE1α/XBP1 pathway and may represent a potential therapeutic target for MASLD intervention.
- 25 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1213
Open AccessCartilage Intermediate Layer Protein 2 Aggravates Hepatic Lipid Accumulation and Inflammation Through the IRE1α/XBP1 Pathway
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and is characterized by excessive lipid accumulation in hepatocytes. Endoplasmic reticulum (ER) stress and inflammation play important roles in hepatic lipid accumulation. Although CILP2 has been implicated in lipid metabolism, its role in MASLD remains unclear. Hepatic steatosis was induced in mice by a high-fat diet in this study. CILP2 was overexpressed in mouse livers and in vitro hepatocytes using the Ad-CILP2 adenovirus. CILP2 KO mice were also used in the experiments. Liver tissues and hepatocytes were collected for further analysis. CILP2 expression was upregulated in steatotic liver tissue and hepatocytes. CILP2 overexpression upregulated genes related to fatty acid synthesis (Srebp-1c, Fasn, Acc, Scd1, and Cd36), promoted lipid accumulation, and elevated the expression of proinflammatory cytokines (Il6, Tnf, and Il1b). Conversely, CILP2 knockout reduced high-fat diet-induced hepatic steatosis and improved glucose metabolism. Mechanistically, CILP2 activated the IRE1α/XBP1 branch of the ER stress pathway, thereby promoting lipid synthesis and inflammation, effects that were partially alleviated by 4-PBA and STF-083010 treatments. Our findings indicate that CILP2 contributes to hepatic lipid accumulation and inflammation via the IRE1α/XBP1 pathway and may represent a potential therapeutic target for MASLD intervention.
- Top Cited PapersOpen Access
- 8 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (12) , 2401-2409
Interaction between diabetes and osteoporosis: imbalance between inflammation and bone remodeling
Diabetes and osteoporosis are common chronic diseases worldwide, and there is a complex pathological relationship between the two. Due to hyperglycemia, insulin resistance, and accumulation of advanced glycation end products (AGEs), diabetic patients often show a higher risk of fractures. At the same time, chronic low-grade inflammation and oxidative stress caused by diabetes also play an important role in the occurrence of osteoporosis, disrupting the balance of bone remodeling. This review deeply explores the effects of chronic inflammation caused by diabetes on the function of osteoblasts and osteoclasts, analyzes the mechanism of increased bone resorption and decreased bone formation during bone remodeling, and summarizes potential therapeutic intervention strategies, such as anti-inflammatory therapy, bone remodeling promoters, and the application prospects of new targeted drugs.
- 8 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (12) , 2401-2409
Top Cited PapersOpen AccessInteraction between diabetes and osteoporosis: imbalance between inflammation and bone remodeling
Diabetes and osteoporosis are common chronic diseases worldwide, and there is a complex pathological relationship between the two. Due to hyperglycemia, insulin resistance, and accumulation of advanced glycation end products (AGEs), diabetic patients often show a higher risk of fractures. At the same time, chronic low-grade inflammation and oxidative stress caused by diabetes also play an important role in the occurrence of osteoporosis, disrupting the balance of bone remodeling. This review deeply explores the effects of chronic inflammation caused by diabetes on the function of osteoblasts and osteoclasts, analyzes the mechanism of increased bone resorption and decreased bone formation during bone remodeling, and summarizes potential therapeutic intervention strategies, such as anti-inflammatory therapy, bone remodeling promoters, and the application prospects of new targeted drugs.
- Open Access
- 8 March 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-18
The collagen-modifying enzyme GLT25D1 is a prognostic indicator related to immunosuppression and malignant phenotypes in hepatocellular carcinoma
The collagen β (1-O) glycosyltransferase 25 domain 1 (GLT25D1), a crucial collagen-modifying enzyme (CME), plays a pivotal role in multiple pathophysiological processes. However, its prognostic and biological roles in hepatocellular carcinoma (HCC) have not been reported. CME-related genes (CMEGs) were obtained from the Molecular Signatures Database (MSigDB), differentially expressed CMEGs (DECMEGs) and prognostic ones were identified. GLT25D1 expression was determined at the mRNA and protein levels in multiple datasets and in our HCC cohort. Its prognostic performance was evaluated and the immune microenvironment was investigated. The effects of GLT25D1 on tumorigenesis were further explored via in vitro and in vivo experiments. Four potential prognosis-associated DECMEGs, including GLT25D1, were identified. GLT25D1 was noticeably up-regulated in HCC tissues and significantly associated with advanced tumor grade and stage. Enrichment analysis revealed that GLT25D1 could participate in regulating immune responses and various carcinogenic processes. HCC patients with high GLT25D1 expression had decreased CD8+ T cells and increased M0 macrophages, leading to an immunosuppressive microenvironment. Our in vivo and in vitro experiments confirmed the increased GLT25D1 expression, and GLT25D1 knockdown impaired the HCC malignant phenotypes. Our results showed that GLT25D1 could be a carcinogenic indicator reflecting poor prognosis and might serve as a potential risk biomarker for HCC patients.
- 8 March 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-18
Open AccessThe collagen-modifying enzyme GLT25D1 is a prognostic indicator related to immunosuppression and malignant phenotypes in hepatocellular carcinoma
The collagen β (1-O) glycosyltransferase 25 domain 1 (GLT25D1), a crucial collagen-modifying enzyme (CME), plays a pivotal role in multiple pathophysiological processes. However, its prognostic and biological roles in hepatocellular carcinoma (HCC) have not been reported. CME-related genes (CMEGs) were obtained from the Molecular Signatures Database (MSigDB), differentially expressed CMEGs (DECMEGs) and prognostic ones were identified. GLT25D1 expression was determined at the mRNA and protein levels in multiple datasets and in our HCC cohort. Its prognostic performance was evaluated and the immune microenvironment was investigated. The effects of GLT25D1 on tumorigenesis were further explored via in vitro and in vivo experiments. Four potential prognosis-associated DECMEGs, including GLT25D1, were identified. GLT25D1 was noticeably up-regulated in HCC tissues and significantly associated with advanced tumor grade and stage. Enrichment analysis revealed that GLT25D1 could participate in regulating immune responses and various carcinogenic processes. HCC patients with high GLT25D1 expression had decreased CD8+ T cells and increased M0 macrophages, leading to an immunosuppressive microenvironment. Our in vivo and in vitro experiments confirmed the increased GLT25D1 expression, and GLT25D1 knockdown impaired the HCC malignant phenotypes. Our results showed that GLT25D1 could be a carcinogenic indicator reflecting poor prognosis and might serve as a potential risk biomarker for HCC patients.
- 6 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (23) , e70245
Circulating DKK1 levels are significantly elevated in obese individuals and are associated with insulin resistance and oxidative stress
Dickkopf‐1 (DKK1) is reportedly involved in various biological functions of the human body. However, the relationship between DKK1 and obesity in humans remains unknown. Bioinformatics analysis was performed to investigate the associations between DKK1 and metabolism‐related genes and signaling pathways. EHC and OGTT were performed on all individuals. Serum DKK1 concentrations were measured by an ELISA kit. DKK1 expression was measured by qRT‐PCR and Western blotting. We found that circulating DKK1 levels in overweight/obese (OW/OB) individuals were significantly elevated and were associated with parameters of glucose/lipid metabolism and IR, including BMI, WHR, fat%, TC, TG, FBG, 2 h‐BG, FIns, 2 h‐Ins, LDL‐C, HbA1c, HOMA‐IR, AUCi, AUCg, BAI, and VAI. The circulating DKK1 concentration was not affected by blood glucose or serum insulin levels. Bioinformatics analysis suggested that DKK1 may be associated with glucose/lipid metabolism and oxidative stress. At the cellular level, we found that DKK1 promoted oxidative stress and inhibited insulin signaling. Circulating DKK1 may be a biomarker for obesity and IR.
- 6 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (23) , e70245
Circulating DKK1 levels are significantly elevated in obese individuals and are associated with insulin resistance and oxidative stress
Dickkopf‐1 (DKK1) is reportedly involved in various biological functions of the human body. However, the relationship between DKK1 and obesity in humans remains unknown. Bioinformatics analysis was performed to investigate the associations between DKK1 and metabolism‐related genes and signaling pathways. EHC and OGTT were performed on all individuals. Serum DKK1 concentrations were measured by an ELISA kit. DKK1 expression was measured by qRT‐PCR and Western blotting. We found that circulating DKK1 levels in overweight/obese (OW/OB) individuals were significantly elevated and were associated with parameters of glucose/lipid metabolism and IR, including BMI, WHR, fat%, TC, TG, FBG, 2 h‐BG, FIns, 2 h‐Ins, LDL‐C, HbA1c, HOMA‐IR, AUCi, AUCg, BAI, and VAI. The circulating DKK1 concentration was not affected by blood glucose or serum insulin levels. Bioinformatics analysis suggested that DKK1 may be associated with glucose/lipid metabolism and oxidative stress. At the cellular level, we found that DKK1 promoted oxidative stress and inhibited insulin signaling. Circulating DKK1 may be a biomarker for obesity and IR.
- Open Access
- 19 November 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (1) , 54-74
Intestinal NUCB2/nesfatin-1 regulates hepatic glucose production via the MC4R-cAMP-GLP-1 pathway
Communication of gut hormones with the central nervous system is important to regulate systemic glucose homeostasis, but the precise underlying mechanism involved remain little understood. Nesfatin-1, encoded by nucleobindin-2 (NUCB2), a potent anorexigenic peptide hormone, was found to be released from the gastrointestinal tract, but its specific function in this context remains unclear. Herein, we found that gut nesfatin-1 can sense nutrients such as glucose and lipids and subsequently decreases hepatic glucose production. Nesfatin-1 infusion in the small intestine of NUCB2-knockout rats reduced hepatic glucose production via a gut – brain – liver circuit. Mechanistically, NUCB2/nesfatin-1 interacted directly with melanocortin 4 receptor (MC4R) through its H-F-R domain and increased cyclic adenosine monophosphate (cAMP) levels and glucagon-like peptide 1 (GLP-1) secretion in the intestinal epithelium, thus inhibiting hepatic glucose production. The intestinal nesfatin-1 -MC4R-cAMP-GLP-1 pathway and systemic gut-brain communication are required for nesfatin-1 - mediated regulation of liver energy metabolism. These findings reveal a novel mechanism of hepatic glucose production control by gut hormones through the central nervous system.
- 19 November 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (1) , 54-74
Open AccessIntestinal NUCB2/nesfatin-1 regulates hepatic glucose production via the MC4R-cAMP-GLP-1 pathway
Communication of gut hormones with the central nervous system is important to regulate systemic glucose homeostasis, but the precise underlying mechanism involved remain little understood. Nesfatin-1, encoded by nucleobindin-2 (NUCB2), a potent anorexigenic peptide hormone, was found to be released from the gastrointestinal tract, but its specific function in this context remains unclear. Herein, we found that gut nesfatin-1 can sense nutrients such as glucose and lipids and subsequently decreases hepatic glucose production. Nesfatin-1 infusion in the small intestine of NUCB2-knockout rats reduced hepatic glucose production via a gut – brain – liver circuit. Mechanistically, NUCB2/nesfatin-1 interacted directly with melanocortin 4 receptor (MC4R) through its H-F-R domain and increased cyclic adenosine monophosphate (cAMP) levels and glucagon-like peptide 1 (GLP-1) secretion in the intestinal epithelium, thus inhibiting hepatic glucose production. The intestinal nesfatin-1 -MC4R-cAMP-GLP-1 pathway and systemic gut-brain communication are required for nesfatin-1 - mediated regulation of liver energy metabolism. These findings reveal a novel mechanism of hepatic glucose production control by gut hormones through the central nervous system.
- Open Access
- 20 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
AZGP1 in POMC neurons modulates energy homeostasis and metabolism through leptin-mediated STAT3 phosphorylation
Zinc-alpha2-glycoprotein (AZGP1) has been implicated in peripheral metabolism; however, its role in regulating energy metabolism in the brain, particularly in POMC neurons, remains unknown. Here, we show that AZGP1 in POMC neurons plays a crucial role in controlling whole-body metabolism. POMC neuron-specific overexpression of Azgp1 under high-fat diet conditions reduces energy intake, raises energy expenditure, elevates peripheral tissue leptin and insulin sensitivity, alleviates liver steatosis, and promotes adipose tissue browning. Conversely, mice with inducible deletion of Azgp1 in POMC neurons exhibit the opposite metabolic phenotypes, showing increased susceptibility to diet-induced obesity. Notably, an increase in AZGP1 signaling in the hypothalamus elevates STAT3 phosphorylation and increases POMC neuron excitability. Mechanistically, AZGP1 enhances leptin-JAK2-STAT3 signaling by interacting with acylglycerol kinase (AGK) to block its ubiquitination degradation. Collectively, these results suggest that AZGP1 plays a crucial role in regulating energy homeostasis and glucose/lipid metabolism by acting on hypothalamic POMC neurons.
- 20 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessAZGP1 in POMC neurons modulates energy homeostasis and metabolism through leptin-mediated STAT3 phosphorylation
Zinc-alpha2-glycoprotein (AZGP1) has been implicated in peripheral metabolism; however, its role in regulating energy metabolism in the brain, particularly in POMC neurons, remains unknown. Here, we show that AZGP1 in POMC neurons plays a crucial role in controlling whole-body metabolism. POMC neuron-specific overexpression of Azgp1 under high-fat diet conditions reduces energy intake, raises energy expenditure, elevates peripheral tissue leptin and insulin sensitivity, alleviates liver steatosis, and promotes adipose tissue browning. Conversely, mice with inducible deletion of Azgp1 in POMC neurons exhibit the opposite metabolic phenotypes, showing increased susceptibility to diet-induced obesity. Notably, an increase in AZGP1 signaling in the hypothalamus elevates STAT3 phosphorylation and increases POMC neuron excitability. Mechanistically, AZGP1 enhances leptin-JAK2-STAT3 signaling by interacting with acylglycerol kinase (AGK) to block its ubiquitination degradation. Collectively, these results suggest that AZGP1 plays a crucial role in regulating energy homeostasis and glucose/lipid metabolism by acting on hypothalamic POMC neurons.